| Keywords: |
mitogen activated protein kinase; protein kinase b; cancer survival; treatment outcome; gene mutation; genetics; mutation; clinical trial; advanced cancer; monotherapy; note; cancer patient; disease free survival; pancreas cancer; antineoplastic agent; endometrium cancer; neoplasm; neoplasms; colorectal cancer; metabolism; lung non small cell cancer; randomized controlled trial; epidermal growth factor receptor; randomized controlled trials as topic; lung cancer; editorial; receptor, epidermal growth factor; drug resistance; drug resistance, neoplasm; cetuximab; phosphatidylinositol 3 kinase; cancer resistance; panitumumab; drug antagonism; head and neck cancer; colon cancer; uterine cervix cancer; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; ras protein; ras proteins; oncogene k ras; b raf kinase; epidermal growth factor receptor antibody; biliary tract cancer; epidermal growth factor receptor kinase inhibitor; oncogene n ras
|
